Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3770898 | 0.98 | TAAR1 (0.52) | TAAR1KMT2AMEN1GAAMAPT | |
| Oxalic Acid SCHEMBL27962739 | 0.92 | GAA (0.51) | TAAR1KMT2AMEN1GAAMAPK1 | |
| SCHEMBL938702 | 0.85 | TAAR1 (0.57) | TAAR1KMT2AMEN1GAAMAPT | |
| SCHEMBL28087397 | 0.85 | TAAR1 (0.57) | TAAR1KMT2AMEN1GAAMAPT | |
| SCHEMBL13644447 | 0.85 | TAAR1 (0.57) | TAAR1KMT2AMEN1GAAMAPT | |
| SCHEMBL28905170 | 0.84 | TAAR1 (0.52) | TAAR1KMT2AMEN1GAAMAPT | |
| Hydrochloric Acid SCHEMBL174859 | 0.84 | TAAR1 (0.55) | TAAR1KMT2AMEN1GAAMAPT | |
| SCHEMBL15100338 | 0.84 | KMT2A (0.54) | TAAR1KMT2AMEN1GAAMAPT | |
| SCHEMBL28134161 | 0.84 | ADRB2 (0.58) | MAPK1KCNH2LMNAKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL28087267 | 0.84 | TAAR1 (0.55) | TAAR1KMT2AMEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784911-A | Synthetic method of 1- [2- (4-chlorophenyl) -ethylamino ] -2-propanol | 山东省药学科学院 | 2023-03-14 | — | — | CN | claimed |
| CN-112358406-A | Preparation method of lorcaserin intermediate | 山东省药学科学院 | 2021-02-12 | — | — | CN | claimed |
| US-20150210625-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. | 2015-07-30 | — | — | US | claimed |
| US-8952197-B2 | Processes for the preparation of 5-HT2C receptor agonists | ARENA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | claimed |
| CN-104119236-A | Synthesis of Lorcaserin and preparation method of intermediate of Lorcaserin | SHANGHAI SCIENPHARM CO LTD | 2014-10-29 | — | — | CN | claimed |
| US-8822727-B2 | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine | ARENA PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | claimed |
| EP-2518053-A1 | PROCESS FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | Arena Pharmaceuticals, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| CN-101466684-B | Preparation process of 8-chloro-1-methyl-2, 3,4, 5-tetrahydro-1H-3-benzazepine and related intermediate thereof | ARENA PHARM INC | 2012-06-20 | — | — | CN | claimed |
| US-20120142967-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | claimed |
| US-8168782-B2 | synthesis of lorcaserin | ARENA PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | claimed |
| EP-2443080-A2 | PROCESS FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| JP-2011513402-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2288585-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES RELATED TO THE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | Arena Pharmaceuticals, Inc. (US) | 2011-03-02 | — | — | EP | claimed |
| US-20110015438-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES RELATED TOTHE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5,-TETRAHYDRO-1H-3-BENZAZEPINE | ARENA PHARMACEUTICALS, INC. | 2011-01-20 | — | — | US | claimed |
| WO-2010148207-A2 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | claimed |
| WO-2009111004-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES RELATED TO THE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | ARENA PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| CN-101466684-A | Preparation process of 8-chloro-1-methyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine and related intermediate thereof | ARENA PHARM INC (US) | 2009-06-24 | — | — | CN | claimed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | claimed |
| EP-2001852-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007120517-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142967-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR3C, HTR5A | TAAR1 155/4885KMT2A 652/4885MEN1 2296/4885 |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | HTR2C, HTR3C, HTR1A | TAAR1 203/4885KMT2A 820/4885MEN1 2190/4885 |
| US-20110015438-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES RELATED TOTHE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5,-TETRAHYDRO-1H-3-BENZAZEPINE | HTR2C, HTR3C, HTR3A | TAAR1 62/4885KMT2A 704/4885MEN1 3087/4885 |
| US-20150210625-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR3C, HTR5A | TAAR1 155/4885KMT2A 652/4885MEN1 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.